Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 6/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | KDM4B | O94953 | 1/20 | 0.43 |
| ▸ | KDM5C | P41229 | 1/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.43 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1234859 | 0.83 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DEGFR | |
| SCHEMBL13899657 | 0.77 | EGFR (0.46) | EGFRKDM4CKDM4AKDM4BKDM5C | |
| SCHEMBL12559902 | 0.75 | EGFR (0.45) | EGFRKDM4CKDM4AKDM4BKDM5C | |
| SCHEMBL3326011 | 0.75 | EGFR (0.45) | EGFRKDM4CKDM4AKDM4BKDM5C | |
| SCHEMBL29375518 | 0.75 | EGFR (0.45) | EGFRKDM4CKDM4AKDM4BKDM5C | |
| SCHEMBL8252687 | 0.75 | EGFR (0.45) | EGFRKDM4CKDM4AKDM4BKDM5C | |
| SCHEMBL4870134 | 0.75 | PI4KA (0.55) | EGFRKDM4CKDM4AKDM4BKDM5C | |
| SCHEMBL6836406 | 0.75 | EGFR (0.45) | EGFRKDM4CKDM4AKDM4BKDM5C | |
| SCHEMBL29650477 | 0.75 | PI4KA (0.55) | EGFRKDM4CKDM4AKDM4BKDM5C | |
| SCHEMBL8128 | 0.72 | GAA (0.45) | EGFRKDM4CKDM4AKDM4BKDM5C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | PLIANT THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| EP-4520329-A2 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4509512-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| EP-4329755-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | Pliant Therapeutics, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4328230-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-117615760-A | Extended dosage regimen for integrin inhibitors | 普利安特治疗公司 | 2024-02-27 | — | — | CN | disclosed |
| US-20240043439-A1 | COMPOUNDS AS C5AR INHIBITORS | KIRA PHARMACEUTICALS (SUZHOU) LTD. (CN) | 2024-02-08 | — | — | US | disclosed |
| EP-3761980-B1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230374024-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2006090167-A2 | HYDRAZINOMETHYL, HYDR ZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006090167-A2 | HYDRAZINOMETHYL, HYDR ZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-08-31 | — | — | WO | disclosed |
| US-6413971-B1 | ANTIPROLIFERATIVE, -CARCINOGENIC, -TUMOR AND -DIABETIC AGENTS; BINDING TO OR MODULATING THE HUMAN KINASE INSERT-DOMAIN-CONTAINING RECEPTOR (KDR) OR THE MURINE FETAL LIVER KINASE 1 (FLK-1) RECEPTOR; VASCULOGENESIS; ANGIOGENESIS | PFIZER INC | 2002-07-02 | — | — | US | disclosed |
| US-6395733-B1 | ANTICANCER AGENTS; ANTIPROLIFERATIVE AGENTS | PFIZER INC | 2002-05-28 | — | — | US | disclosed |
| US-20020045630-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | ARNOLD LEE DANIEL (US) | 2002-04-18 | — | — | US | disclosed |
| EP-0946554-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| EP-0831829-A4 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER (US) | 1998-11-25 | — | — | EP | disclosed |
| WO-1998023613-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1998-06-04 | — | — | WO | disclosed |
| EP-0831829-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040142-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045630-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | REV1, DPYD, CCNA1 | PDE4A 3542/4885PDE4B 3322/4885PDE4C 3549/4885 |
| US-20230374024-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, ERBB3, MAP3K6 | PDE4A 1910/4885PDE4B 1873/4885PDE4C 2405/4885 |
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | ITGB6, ITGA6, ITGAV | PDE4A 3891/4885PDE4B 3849/4885PDE4C 4382/4885 |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | PDE4A 3921/4885PDE4B 3861/4885PDE4C 4299/4885 |
| US-20240043439-A1 | COMPOUNDS AS C5AR INHIBITORS | C5AR1, C5AR2, C3AR1 | PDE4A 983/4885PDE4B 745/4885PDE4C 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.